Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Boston Scientific Corp (BSX)

Boston Scientific Corp (BSX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 105,875,192
  • Shares Outstanding, K 1,483,885
  • Annual Sales, $ 20,074 M
  • Annual Income, $ 2,898 M
  • EBIT $ 4,509 M
  • EBITDA $ 5,923 M
  • 60-Month Beta 0.69
  • Price/Sales 5.40
  • Price/Cash Flow 18.09
  • Price/Book 4.43

Options Overview Details

View History
  • Implied Volatility 41.36% (+0.28%)
  • Historical Volatility 60.07%
  • IV Percentile 97%
  • IV Rank 67.94%
  • IV High 52.68% on 04/04/25
  • IV Low 17.38% on 07/29/25
  • Expected Move (DTE 4) 2.08 (2.90%)
  • Put/Call Vol Ratio 3.61
  • Today's Volume 30,881
  • Volume Avg (30-Day) 26,032
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 403,286
  • Open Int (30-Day) 420,081
  • Expected Range 69.82 to 73.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 32 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.80
  • Number of Estimates 10
  • High Estimate 0.86
  • Low Estimate 0.78
  • Prior Year 0.75
  • Growth Rate Est. (year over year) +6.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
69.52 +3.42%
on 03/09/26
76.87 -6.47%
on 02/27/26
-2.22 (-3.00%)
since 02/09/26
3-Month
69.52 +3.42%
on 03/09/26
100.90 -28.74%
on 01/08/26
-20.63 (-22.30%)
since 12/09/25
52-Week
69.52 +3.42%
on 03/09/26
109.50 -34.34%
on 09/09/25
-27.23 (-27.47%)
since 03/07/25

Most Recent Stories

More News
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm, Encourages Boston Scientific Corporation (BSX) Shareholders to Inquire About Securities Fraud Class Action

Glancy Prongay Wolke & Rotter LLP , a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or...

BSX : 71.90 (+0.77%)
BSX Investors Have Opportunity to Join Boston Scientific Corporation Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or...

BSX : 71.90 (+0.77%)
BSX Investors Have Opportunity to Lead Boston Scientific Corporation Securities Fraud Lawsuit

NEW YORK , March 6, 2026 /PRNewswire/ --

BSX : 71.90 (+0.77%)
Law Offices of Howard G. Smith Encourages Boston Scientific Corporation (BSX) Shareholders To Inquire About Securities Fraud Class Action

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE:...

BSX : 71.90 (+0.77%)
BSX Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Boston Scientific Corporation

SAN DIEGO , March 6, 2026 /PRNewswire/ -- Robbins LLP  reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Boston Scientific Corporation...

BSX : 71.90 (+0.77%)
Rosen Law Firm Urges Boston Scientific Corporation (NYSE: BSX) Stockholders to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Boston Scientific Corporation (NYSE: BSX) between July 23, 2025 and February...

BSX : 71.90 (+0.77%)
Boston Scientific to host investor event at the 75th Annual Scientific Session of the American College of Cardiology

MARLBOROUGH, Mass. , March 6, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will host an investor event and live webcast on Saturday, March 28, 2026, at 6:30 p.m. ET / 5:30 p.m....

BSX : 71.90 (+0.77%)
Investor Notice: Robbins LLP Informs Investors of the Boston Scientific Corporation Class Action Lawsuit

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Boston Scientific Corporation (NYSE: BSX) common stock between July...

BSX : 71.90 (+0.77%)
1 Healthcare Stock to Target This Week and 2 Facing Challenges

1 Healthcare Stock to Target This Week and 2 Facing Challenges

BSX : 71.90 (+0.77%)
BKD : 14.45 (-2.96%)
AVTR : 8.15 (-0.24%)
Boston Scientific (BSX): Buy, Sell, or Hold Post Q4 Earnings?

Boston Scientific (BSX): Buy, Sell, or Hold Post Q4 Earnings?

BSX : 71.90 (+0.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and...

See More

Key Turning Points

3rd Resistance Point 75.86
2nd Resistance Point 74.11
1st Resistance Point 73.01
Last Price 71.90
1st Support Level 70.16
2nd Support Level 68.41
3rd Support Level 67.31

See More

52-Week High 109.50
Fibonacci 61.8% 94.23
Fibonacci 50% 89.51
Fibonacci 38.2% 84.79
Last Price 71.90
52-Week Low 69.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar